Nano-X Imaging

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Neve Ilan, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nano-X Imaging reports progress in regulatory clearances and strategic partnerships

Nano-X Imaging showcased progress in regulatory clearances, commercialization efforts, strategic partnerships, and operational optimization during the Q4 2022 Earnings Call.
Despite challenges in regulatory compliance, expenses management, and market competition, the company's strengths in innovation, partnerships, and financial resilience position it well for future growth.
Opportunities for Nano-X Imaging include global expansion, technological advancements, cost efficiencies, and leveraging market demand for imaging solutions.
Overall, Nano-X Imaging's performance in Q4 2022 reflects a strategic focus on growth, innovation, and market expansion in the medical imaging industry.

Nano-X Imaging reports improved Q1 performance and expands global reach

Nano-X Imaging's Q1 2023 performance showed improvement with a reported net loss of $11.8 million and revenue of $2.4 million. The company is focusing on deploying Nanox.ARC globally, strengthening manufacturing capabilities, and expanding market reach through strategic partnerships. Challenges include managing expenses and driving revenue growth to achieve profitability.

Nanox Imaging reports Q2 results, eyes U.S. market growth

Nanox Imaging's Q2 2023 performance reflects investment in growth initiatives, with a focus on market expansion and product deployment.
The company faces financial challenges, including a significant net loss and accrued expenses related to an SEC investigation, necessitating prudent financial management.
Strategic strengths in the U.S. market entry, global commercialization efforts, and strong cash position position Nanox Imaging for future growth and market success.
Opportunities lie in upcoming Investor Day, FDA clearance for Nanox.ARC, and expansion in Africa, offering avenues for revenue growth and market leadership.

Nanox Imaging reports Q3 revenue growth and strategic advancements

Nanox Imaging's Q3 2023 performance showed revenue growth and strategic advancements. While facing financial challenges and potential execution hurdles, the company's focus on expansion and partnerships positions it for future growth.

Nanox Imaging reports Q4 loss, eyes global expansion and AI

Nanox Imaging's Q4 2023 performance showed a mix of revenue growth and strategic investments in technology and market expansion.
The company's strengths lie in its progress with regulatory clearances, commercialization efforts, and success in AI applications.
Challenges include slow AI adoption, implementation hurdles, and the need to overcome barriers to data sharing and transparency.
Opportunities exist in expanding HealthCCS usage, global market presence, and addressing AI adoption challenges for revenue growth.

Nanox Imaging reports Q1 loss, eyes global expansion and AI growth

Nanox Imaging's Q1 2024 performance reflects revenue generation from AI solutions and system sales amid challenges in gross profit margins and a notable net loss.
The company's strategic strengths in partnerships, product launches, and global expansions position it well for future growth and market competitiveness.
While facing challenges in cost management and profitability, Nanox Imaging holds opportunities in expanded indications, market expansions, and AI solutions deployment.

Nano-X Imaging reports Q2 losses, eyes growth through FDA clearances

Nano-X Imaging (NNOX) showcased progress in commercial and clinical fronts but faces challenges in narrowing losses and optimizing operations.
Strategic collaborations, FDA clearances, and global deployment offer opportunities for growth and market expansion.
The focus on transformative imaging solutions and commercial infrastructure acceleration underlines NNOX's commitment to innovation and market leadership.

Nanox Imaging reports mixed Q3 results amidst growth opportunities

Nanox Imaging reported mixed financial results with revenue of $3.0 million and a gross loss of $2.8 million, while achieving record revenue from USARAD business.
The company showcased strengths in technology deployment, partnerships, and clinical trials, but faces challenges in regulatory clearances and financial performance.
Opportunities exist in market expansion, revenue growth, and operational efficiency improvements to drive future success and profitability.
With a strong focus on innovation, partnerships, and market expansion, Nanox is poised for growth but needs to address regulatory hurdles and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Petach Tikva, Israel.

Management to host conference call and webcast at 8:30 AM ET Management to host conference call and webcast at 8:30 AM ET

Nanox to Announce Fourth Quarter and Full Year 2020 Financial and Operating Results on Tuesday, March 2, 2021

NEVE ILAN, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it has priced the previously announced underwritten public offering of 3,091,635 of its ordinary shares by certain non-officer, non-director shareholders (the “selling shareholders”) at a public offering price of $62.50 per share. The offering is expected to close on or about February 16, 2021, subject to satisfaction of customary closing conditions.

Nanox Announces Pricing of Secondary Offering of Ordinary Shares

Some early investors are cashing out, and that almost caused investors to overlook this encouraging news.

Why Nano-X Imaging Stock Plummeted and Then Soared Today

NEVE ILAN, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced the commencement of a proposed underwritten public offering of 2,891,322 of its ordinary shares by certain non-officer, non-director shareholders (the “selling shareholders”).

Nanox Announces Secondary Offering of Ordinary Shares

And why February may not be shaping up quite as well.

Why Nano-X Imaging Stock Was Up an Impressive 66% in January

Nano Dimension

Both companies are using nanotechnology to revolutionize healthcare and manufacturing. Plus, they have considerable upside.

Have $3,000? Buying These 2 Stocks Would Be the Smartest Move You Ever Made

Foley Trasimene Acquisition Corp. II

Dragoneer Growth Opportunities Corp.

Dragoneer Growth Opportunities Corp. II

GS Acquisition Holdings Corp

Longview Acquisition Corp.

Many SPAC Stocks Will Offer Significant Upside In 2021, Here Are My Top Picks

Amphastar Pharma

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Colfax

Crh Medical

Global Blood Therapeutics

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

Lexicon Pharmaceuticals

MannKind

Nektar Therapeutics

ObsEva

Personalis Inc

PIMCO Corporate & Income Opportunity Fund

Construction Partners

Surgery Partners

SP Plus

Takeda Pharmaceutical

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

The stock price of Nano-X Imaging Ltd. (NASDAQGS: NNOX) increased by 26.21% on Thursday January 21.

NNOX Stock Price Increased 26.21%: Why It Happened

New Chief Operating Officer, Chief Technology Officer and Chief Marketing Officer to support Company's mission to democratize medical imaging globally

Nanox Announces Three Key Senior Level Hires to Support Long-Term Growth Objectives

NEVE ILAN, Israel and FORT LAUDERDALE, Fla, Jan. 11, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announces that Nanox's Founder and Chief Executive Officer Ran Poliakine will deliver a company presentation and the leadership team will host investor 1x1 meetings during the Virtual 39th Annual J.P. Morgan Healthcare Conference, which is being held from January 11 through January 14.

Nanox to Participate in the Virtual 39th Annual J.P. Morgan Healthcare Conference

The controversial stock cooled off after a hot November as investors await regulatory approval in 2021.

Why Nano-X Imaging Stock Dropped 26% in December

Platform offers first of its kind service based on a 300+ radiologist network and over 20 FDA 510(k)-cleared artificial intelligence algorithms to support medical diagnostic industry

Nanox and USARAD Introduce Radiology AI Second Opinion Program

Teladoc

Trillium Therapeutics

Find out what these healthcare businesses can do to deliver big gains this year.

3 Healthcare Stocks That Could Soar In 2021

Eargo

Outset Medical

Silk Road Medical Inc

Transmedics Group Inc

LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road Medical, Inc. (NASDAQ:SILK) as best Health-Tech companies to watch in 2021-2022. The report provides an overview and brief assessment of 5 highly impactful and promising medical hardware technologies to be watched in 2021-2022, and the companies behind their development and commercialization. In the case

Deep Pharma Intelligence Names Nanox, TransMedics, Outset, Eargo, and Silkroad as Best Health-Tech Companies to Watch in 2021-2022

There hasn't been an innovation in X-ray imaging in more than 120 years. This mid-cap medical device company seeks to change that -- with a bit of a caveat.

Why Is Everyone Talking About Nano-X Imaging Stock?

Nano-X Vision Under The X-Ray

Shares of the medical imaging specialist soared on anticipation of its big reveal.

Why Nano-X Imaging Jumped 122% in November

Live demonstration featured a range of 2D and 3D imaging procedures Live demonstration featured a range of 2D and 3D imaging procedures

Nanox Announces Successful Demonstration of the Nanox.ARC Prototype During RSNA 2020

As the company prepares to demo its X-ray machine tomorrow, investors hedge their bets.

Why Nano-X Imaging Stock Just Crashed 10%

In two days, Nano-X may change the story on its stock forever.

Why Nano-X Imaging Stock Continues to Surge

Live demonstration now scheduled for 11:30am EST on Thursday, December 3

Nanox Announces Revised Time of Live Demonstration at the 2020 Radiology Society of North America Virtual Annual Meeting

As we close in on Dec. 3 -- the day Nano-X will demonstrate its device to the Radiological Society of North America -- the bulls are charging and the shorts are fleeing. The stock jumped 17% on Monday.

Nano-X Stock Is Heading Higher

Company to host investor webinar following the live demonstration on the same day Company to host investor webinar following the live demonstration on the same day

Nanox to Feature Nanox.ARC Digital X-Ray Technology in a Live Demonstration at the 2020 Radiology Society of North America Virtual Annual Meeting

New York, New York--(Newsfile Corp. - November 16, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Nano-X Imaging Ltd. (NASDAQ: NNOX) alleging that the Company violated federal securities laws.Class Period: August 21, 2020 and September 15, 2020Lead Plaintiff Deadline: November 16, 2020Learn more about your recoverable losses in NNOX:

NNOX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 16, 2020 in the Class Action Filed on Behalf of Nano-X Imaging Ltd. Limited Shareholders

News for Nano-X Imaging Stock (NNOX)